Smith & Nephew Sees Growth Amid China Challenges
Company Announcements

Smith & Nephew Sees Growth Amid China Challenges

Smith & Nephew Snats (SNN) has released an update.

Smith & Nephew reported a 4% revenue growth in Q3 2024, reaching $1,412 million, despite facing challenges in China. The company’s Advanced Wound Management segment showed significant acceleration, while Sports Medicine and Orthopaedics also contributed to the positive performance, driven by the 12-Point Plan improvements. Looking ahead, the company anticipates revenue growth to continue, albeit with caution due to ongoing headwinds in China.

For further insights into SNN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskSmith & Nephew Reports Q3 Growth Amid China Challenges
TipRanks Auto-Generated NewsdeskSmith & Nephew Announces Upcoming Dividend Payout
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App